Mabtas N 500 mg Injection
$479.94
$322.98
Mabtas N 500 mg Injection is a powerful monoclonal antibody designed to target and modulate the immune system, making it an effective treatment option for various conditions, particularly certain cancers such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia. By specifically binding to cancer cells, Mabtas N helps to inhibit their growth and promote the body’s natural defenses against malignant cells. It is crucial for patients to be aware of potential side effects, including infusion-related reactions and an increased risk of infections, which necessitates careful monitoring during treatment. This medication is administered under the guidance of a healthcare professional, ensuring the safest and most effective use. Patients receiving Mabtas N should also inform their doctor of any pre-existing conditions or medications, as these factors can influence treatment outcomes. With its targeted approach, Mabtas N represents a significant advancement in cancer therapy, offering hope to those battling these challenging diseases. Always discuss the benefits and risks with your healthcare provider to determine if Mabtas N is the right choice for your treatment plan.
मात्रा
Active Pharmaceutical Ingredient
Uses
• Mabtas n 500 mg injection is primarily used in the treatment of non-Hodgkin lymphoma (NHL). This type of cancer affects the lymphatic system, which is a critical part of the immune system. By using Mabtas n 500 mg injection, healthcare providers aim to target and reduce the proliferation of malignant cells. This treatment can help improve the overall prognosis for patients diagnosed with NHL.
• Another key application of Mabtas n 500 mg injection is in managing rheumatoid arthritis. This chronic inflammatory condition can lead to joint damage and significant pain. Mabtas n 500 mg injection works by modulating the immune response, thus helping to alleviate symptoms and improve joint function. Patients receiving this treatment often experience a reduction in inflammation and enhanced quality of life.
• Mabtas n 500 mg injection is also indicated for the treatment of chronic lymphocytic leukaemia (CLL), a type of blood cancer that affects the white blood cells. The injection aids in targeting the abnormal cells, helping to control the disease's progression. By incorporating Mabtas n 500 mg injection into their treatment regimen, patients may see improvements in their overall health status and blood cell counts. This targeted approach can be crucial for effective disease management.
• In addition, Mabtas n 500 mg injection is utilized in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis. These are rare autoimmune conditions that cause inflammation of blood vessels, leading to various complications. The administration of Mabtas n 500 mg injection helps to suppress the inappropriate immune response, thereby reducing inflammation and preventing further damage. This targeted therapy can be essential for maintaining patient stability and improving long-term outcomes.
Benefits
Non-Hodgkin lymphoma (NHL): Non-Hodgkin's lymphoma is a form of cancer that affects the white blood cells in the body. These cells are responsible for preventing infections. Mabtas 500 mg Vial has been demonstrated to reduce the immune response and relieve pain and inflammation. It also can kill cancer cells and prevent their further growth. To prevent the spread of infection, it is advisable to avoid crowds and to wash your hands frequently. It is recommended that patients consume an adequate quantity of fluids unless otherwise advised by their physician. Rheumatoid arthritis: Rituximab Injection 500 mg is an immunosuppressant that is used to treat rheumatoid arthritis. It is administered in a dose and frequency that is tailored to the patient's condition. This is determined by the physician. It is crucial to adhere to the physician's instructions and to promptly report any adverse effects, including fever, chills, or other symptoms, to the physician. Blood cancer (Chronic lymphocytic leukaemia): Leukaemia, also known as blood cancer, is a malignant neoplasm of the haematopoietic tissues that impairs the body's ability to combat infection. Mabtas N 500 mg is a chemotherapeutic agent that kills or inhibits the proliferation of malignant cells and is effective in the treatment of leukaemia. However, it is important to discuss the potential side effects and benefits of this medication with a qualified healthcare professional. It is also essential to inform your doctor of any adverse effects that may arise during treatment. Granulomatosis with polyangiitis: Granulomatosis with polyangiitis (GPA) is a condition that causes inflammation of the blood vessels of the ears, nose, throat, lungs, and kidneys. In this condition, the blood flow to these areas may be reduced, which can lead to their damage. Mabtas N Injection is an effective treatment that helps reduce inflammation, pain, and swelling and prevents further damage. This improves the quality of life of those affected by GPA. Microscopic polyangiitis: Microscopic polyangiitis is an autoimmune disease that affects the small blood vessels and may be caused by an imbalance in the immune system. Mabtas N 500 mg reduces the immune response and improves inflammation. This helps to heal the condition and to alleviate discomfort.
Side Effects
Mabtas N 500 mg Injection can cause various adverse effects that can differ from one person to another. Some of the adverse effects of the drug are listed below.
Most Common Side Effects
• Low Immunity
• Nausea
• Tinnitus
• Muscle Pain and Stiffness
• Face Swelling
• Low Blood Count of White Blood Cells and Red Blood Cells
• Increase in Glucose Levels in Blood
• Headache
Common Side Effects
• Skin Reactions
• Heart Problems
• Infections
• Allergies
How To Use
The administration of Mabtas 500 mg Vial is typically conducted by a medical professional, such as a doctor or nurse, in a medical facility, such as a hospital or clinic. It is not advisable to administer the product independently, and it is important to adhere to the instructions provided by a qualified healthcare professional.
Safety Advice
• Alcohol: Caution should be exercised when drinking alcohol with Rituximab Injection 500 mg. Please consult your doctor.
• Kidney: Mabtas N 500 mg is likely to be safe in patients with kidney disease. The limited data available suggest that dose adjustment of Vortuxi Solution for Infusion may not be necessary for these patients. Please consult your doctor.
• Breastfeeding: Mabtas N 500 mg Injection is likely to be safe to use while breast-feeding, and limited human statistics support that the drug now no longer poses a good risk to the baby.
• Liver: Mabtas 500 mg Vial is not recommended in patients with active liver disease or those who have had viral hepatitis. Please consult your doctor.
• Pregnancy: Mabtas Rituximab 500 mg may not be safe for use during pregnancy. Although there is limited human research, animal research has shown dangerous effects on the growing baby. Your doctor will weigh up the benefits and potential risks before prescribing it to you. Please consult your doctor.
• Driving: It is not known whether Rituximab Injection 500 mg affects your ability to drive. Do not drive if you experience symptoms that affect your ability to concentrate and react.